EW (Edwards Lifesciences) EBIT: $1,398 Mil (TTM As of Mar. 2026)


EW Edwards Lifesciences Corp EW
97 GF Score
Price $89.66
GF Value $93.14
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences EBIT?

Edwards Lifesciences EW +3.12% 97 EBIT is $1,398 Mil as of Mar. 2026. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.14 (Fairly Valued). The stock has 5 warning signs investors should review.

Edwards Lifesciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $515 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $1,398 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Edwards Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 was 20.30%. Edwards Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 77.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Edwards Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.87%.


Edwards Lifesciences  (NYSE:EW) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Edwards Lifesciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2058.8 * ( 1 - 17.06% )/( (8251.7 + 8568.3)/ 2 )
=1707.56872/8410
=20.30 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Edwards Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2058.8/( ( (1914.6 + max(470.9, 0)) + (1922.4 + max(975.2, 0)) )/ 2 )
=2058.8/( ( 2385.5 + 2897.6 )/ 2 )
=2058.8/2641.55
=77.94 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(659.6 + 1126.2 + 474.3) - (1219.2 + 27.2 + 542.8)
=470.9

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(775.7 + 1119 + 465.2) - (1081.4 + 22.8 + 280.5)
=975.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Edwards Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1398.1/48657.628
=2.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edwards Lifesciences EBIT Related Terms


Edwards Lifesciences EBIT Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences EBIT Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,720.40 1,538.70 1,390.00 1,567.90 1,293.30

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 409.90 430.90 425.10 27.40 514.70

EW vs DXCM, GEHC, BSX: EBIT Comparison

For the Medical Devices subindustry, Edwards Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's EV-to-EBIT falls into.


EW
97GF Score
Edwards Lifesciences Corp EW
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,398 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $1,398 Mil mean?
Edwards Lifesciences (EW) has a EBIT of $1,398 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edwards Lifesciences.
Is Edwards Lifesciences' EBIT too high?
Edwards Lifesciences' current EBIT is $1,398 Mil. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EBIT compare to DXCM and GEHC?
Edwards Lifesciences' EBIT of $1,398 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Edwards Lifesciences. Edwards Lifesciences's current EBIT is $1,398 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.14, compared to a current price of $89.66 — trading 3.7% below its estimated fair value. The current EBIT is $1,398 Mil. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current EBIT is $1,398 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of $89.66 is trading 3.7% below its estimated GF Value™ of $93.14. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for EW:

  • EBIT: $1,398 Mil
  • GF Value™: $93.14 vs. price of $89.66 (3.7% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score

Get the complete analysis for EW

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.66
Price
$93.14
GF Value